Jun 19, 2020
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China
Jun 12, 2020
EHA25Virtual: A Safe and Strikingly Effective Biologic Therapy for the World's Second Most Common Hereditary Bleeding Disorder
May 29, 2020
PathAI Demonstrates the Potential of AI-based Characterization of the Tumor Microenvironment at ASCO
Apr 22, 2020
REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
Nov 01, 2019
Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Oct 11, 2019
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
Sep 19, 2019
Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO
Sep 12, 2019
Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting
Sep 04, 2019
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
Aug 20, 2019
BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME
Jul 24, 2019
First Patient Dosed in Sintilimab and Anti-VEGF Monoclonal Antibody IBI305 with Chemotherapy in Patients with EGFR-mutant Non-squamous NSCLC who have Progressed from Prior EGFR-TKI Treatment
Jun 26, 2019
Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) Overview 2019: An Oral Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1), VEGFR-2, & VEGFR-3
Jun 02, 2019
Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab
May 30, 2019
REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD
Apr 25, 2019
Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
Apr 17, 2019
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD
Apr 04, 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Apr 02, 2019
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol
Apr 01, 2019
Araim's Cibinetide Enhances Endothelial Stem Cell Mediated Vascular Regeneration for Treatment of Retinal Ischemia
Feb 27, 2019
First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma